FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Sanfilippo Jennifer A

 2. Date of Event Requiring Statement (MM/DD/YYYY)
9/5/2019 

 3. Issuer Name and Ticker or Trading Symbol

MELINTA THERAPEUTICS, INC. /NEW/ [MLNT]

(Last)        (First)        (Middle)

C/O MELINTA THERAPEUTICS, INC., 44 WHIPPANY ROAD

 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
interim Chief Executive Office /

(Street)

MORRISTOWN, NJ 07960      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)

 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Melinta Common Stock 600 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Melinta Stock Option (right to buy)  (1)4/19/2028 Melinta Common Stock 5600.0 $37.25 D  
Melinta Restricted Stock Units  (2) (2)Melinta Common Stock 120000.0  (2)D  
Explanation of Responses:
(1) One quarter of the shares vested on April 20, 2019, and the rest vest in essentially equal monthly amounts during the 36 month period beginning April 21, 2019.
(2) The restricted stock units will vest in equal semi-annual installments over the two year period following May 16, 2019, subject to continued service with the Issuer through the applicable vesting date.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Sanfilippo Jennifer A
C/O MELINTA THERAPEUTICS, INC.
44 WHIPPANY ROAD
MORRISTOWN, NJ 07960		X
interim Chief Executive Office
Signatures
Russell E Causey9/13/2019
**Signature of Reporting PersonDate
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Melinta Therapeutics Charts.
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Melinta Therapeutics Charts.